pharmaceutical deals, page-106

Taken from October 2017 investor presentation. Could be the infrastructure to support the following-

Trofinetide development program
Investments ongoing before commencement of Phase 3 trial:
 Conclude optimization of API manufacturing process for commercial supply
 Conclude stability testing and analytical validation of to‐be‐marketed liquid drug formulation
 Conduct non‐clinical toxicity study in second species with 6 months’ dosing, required for NDA and Phase 3 trial with longer dosing
 Schedule manufacturing to supply the Phase 3 trial